Systemic therapies for salivary gland carcinomas: an overview of published clinical trials.
Med Oral Patol Oral Cir Bucal
; 29(2): e280-e287, 2024 03 01.
Article
em En
| MEDLINE
| ID: mdl-38150606
ABSTRACT
BACKGROUND:
There is no consensus about effective systemic therapy for salivary gland carcinomas (sgcs). Our aim was summarized the clinical trials assessing the systemic therapies (ST) on sgcs. MATERIAL ANDMETHODS:
Electronic searches were carried out through MEDLINE/pubmed, EMBASE, Scopus, Web of Science, and the Cochrane Library databases, and gray literature.RESULTS:
Seventeen different drugs were evaluated, and the most frequent histological subtype was adenoid cystic carcinoma (n=195, 45.5%). Stable disease, observed in 11 ST, achieved the highest rate in adenoid cystic carcinoma treated with sunitinib. The highest complete (11.1%) and partial response (30.5%) rates were seen in androgen receptor-positive tumors treated with leuprorelin acetate.CONCLUSIONS:
Despite all the advances in this field, there is yet no effective evidence-based regimen of ST, with all the clinical trials identified showing low rates of complete and partial responses. Further, translational studies are urgently required to characterize molecular targets and effective ST.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias das Glândulas Salivares
/
Carcinoma Adenoide Cístico
Limite:
Humans
Idioma:
En
Revista:
Med Oral Patol Oral Cir Bucal
Assunto da revista:
ODONTOLOGIA
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Brasil